SRPT Jan 2025 190.000 call
- PR Newswire
Sarepta Therapeutics Set to Join S&P MidCap 400
Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE: JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.
- Insider Monkey
Is Sarepta Therapeutics, Inc. (NASDAQ:SRPT) A Good Fast Growth Stock To Buy?
We recently compiled the list of the 10 Best Fast Growth Stocks To Buy according to the hedge funds using the latest sentiment data. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other fast growth stocks. Sarepta Therapeutics recently beat earnings expectations. They are […]
- Zacks
Implied Volatility Surging for Sarepta (SRPT) Stock Options
Investors need to pay close attention to Sarepta (SRPT) stock based on the movements in the options market lately.
